Drug Trial Radar · NCT05614739
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
677
Planned (sponsor's estimate)
Start
Jan 12, 2023
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Nov 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.
Conditions
- Urinary Bladder Neoplasms
- Neoplasm Metastasis
- Ureteral Neoplasms
Interventions
VepugratinibDrug
Oral
PembrolizumabDrug
IV
enfortumab vedotinDrug
IV
Trastuzumab DeruxtecanDrug
IV
MidazolamDrug
Oral
DigoxinDrug
Oral
RosuvastatinDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Up to Approximately 30 Months or 2.5 Years
- Pharmacokinetics (PK) of Vepugratinib: Area Under the Concentration versus Time Curve (AUC)Time frame: Up to 2 Months
- PK of Midazolam, Rosuvastatin, and Digoxin Administered Alone and in the Presence of Vepugratinib: Area Under the Concentration versus Time Curve (AUC[0-inf])Time frame: Up to 2 Months
- Complete Response Rate (CRR) in Participants with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG IR NMIBC)Time frame: Up to approximately 24 months or 5 years
Locations
83 sites in 14 countries. Site status is shown where the registry gives one.
University of Arizona - Cancer Center
Tucson, Arizona · Recruiting
City of Hope
Duarte, California · Recruiting
University of California, Los Angeles (UCLA) - Division of Hematology-Oncology
Los Angeles, California · Recruiting
University of California - Irvine
Orange, California · Recruiting
University of California (UC) Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Stanford Medicine Cancer Center
Stanford, California · Recruiting
Advent Health
Orlando, Florida · Recruiting
Emory University Hospital
Atlanta, Georgia · Recruiting
The University of Chicago Medical Center (UCMC)
Chicago, Illinois · Recruiting
Indiana University (IU) Melvin and Bren Simon Cancer Center
Indianapolis, Indiana · Recruiting
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana · Recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana · Recruiting
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Washington University in St. Louis
St Louis, Missouri · Recruiting
New York University (NYU)
New York, New York · Recruiting
Weill Cornell Medicine
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Columbia University
New York, New York · Recruiting
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of Rochester - Wilmot Cancer Institute
Rochester, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
University of North Carolina (UNC) - Chapel Hill
Chapel Hill, North Carolina · Recruiting
University of Cincinnati Medical Center (UCMC)
Cincinnati, Ohio · Recruiting
The Ohio State University (OSU)
Columbus, Ohio · Recruiting
University of Oklahoma - Health Sciences Center
Oklahoma City, Oklahoma · Recruiting
Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute
Lancaster, Pennsylvania · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
Allegheny General Hospital
Pittsburgh, Pennsylvania · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Recruiting
Sarah Cannon and HCA Research Institute
Nashville, Tennessee · Recruiting
Tennessee Oncology
Nashville, Tennessee · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
University of Texas Southwestern
Dallas, Texas · Recruiting
Texas Oncology, P.A
Dallas, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.